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Cyclooxyganase-2 (COX-2), a rate-limiting enzyme in
the prostaglandin synthesis pathway, is overexpressed in
many cancers and contributes to cancer progression
through tumor cell-autonomous and paracrine effects.
Regular use of non-steroidal anti-inﬂammatory drugs or
selective COX-2 inhibitors (COXIBs) reduces the risk of
cancer development and progression, in particular of the
colon. The COXIB celecoxib is approved for adjunct
therapy in patients with Familial adenomatous polyposis
at high risk for colorectal cancer (CRC) formation.
Long-term use of COXIBs, however, is associated with
potentially severe cardiovascular complications, which
hampers their broader use as preventive anticancer agents.
In an effort to better understand the tumor-suppressive
mechanisms of COXIBs, we identiﬁed MAGUK with
Inverted domain structure-1 (MAGI1), a scaffolding
protein implicated in the stabilization of adherens junc-
tions, as a gene upregulated by COXIB in CRC cells and
acting as tumor suppressor. Overexpression of MAGI1 in
CRC cell lines SW480 and HCT116 induced an epithelial-
like morphology; stabilized E-cadherin and b-catenin
localization at cell–cell junctions; enhanced actin stress
ﬁber and focal adhesion formation; increased cell adhesion
to matrix proteins and suppressed Wnt signaling,
anchorage-independent growth, migration and invasion
in vitro. Conversely, MAGI1 silencing decreased E-
cadherin and b-catenin localization at cell–cell junctions;
disrupted actin stress ﬁber and focal adhesion formation;
and enhanced Wnt signaling, anchorage-independent
growth, migration and invasion in vitro. MAGI1 over-
expression suppressed SW480 and HCT116 subcutaneous
primary tumor growth, attenuated primary tumor growth
and spontaneous lung metastasis in an orthotopic model of
CRC, and decreased the number and size of metastatic
nodules in an experimental model of lung metastasis.
Collectively, these results identify MAG1 as a COXIB-
induced inhibitor of the Wnt/b-catenin signaling pathway,
with tumor-suppressive and anti-metastatic activity in
experimental colon cancer.
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Introduction
Colorectal cancer (CRC) development is a multistep
process (Ilyas et al., 1999). Activation of the Wnt/
b-catenin pathway is considered as a critical initiating
event in the majority of human CRCs (Fodde and
Brabletz, 2007). The Wnt/b-catenin pathway is negatively
regulated by the adenomatous polyposis coli (APC)
tumor-suppressor protein, which targets b-catenin to
proteosomal degradation, and by the cell–cell adhesion
molecule E-cadherin, which sequesters b-catenin to the
cell membrane. The Wnt/b-catenin pathway can be
activated through inhibition of b-catenin degradation or
loss of E-cadherin, thereby causing the accumulation of
b-catenin in the cytoplasm and its translocation to the
nucleus. In the nucleus, b-catenin forms a complex with
the T-cell factor/lymphoid enhancer-binding factor-1
(TCF/LEF1) transcription factor to control gene expres-
sion (Clevers, 2006). Familial adenomatous polyposis
patients have APC mutations preventing b-catenin
degradation, and develop multiple intestinal polyps
progressing to CRC at an early age. At least one APC
allele is mutated in about 60% of sporadic CRCs and
somatic b-catenin mutations are found in 50% of CRCs
with wild-type (WT) APC alleles, further emphasizing
the importance of the Wnt/b-catenin pathway in CRC
development (Fodde and Brabletz, 2007).
A signiﬁcant increase in cyclooxygenase-2 (COX-2,
also known as PTGS2) levels occurs during colorectal
carcinogenesis (Gupta, 2001). Epidemiological studies
showed that regular intake of non-steroidal anti-
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inﬂammatory drugs (for example, aspirin) or selective
COX-2 inhibitors (COXIBs, for example, celecoxib)
decreases the risk of developing CRC (Wang and
Dubois, 2006). Celecoxib (2 400mg/day) was shown
to signiﬁcantly reduce the number of colorectal and
duodenal polyps in familial adenomatous polyposis
patients (Steinbach et al., 2000), and is now approved
as adjunctive therapy to decrease the risk of CRC
development in familial adenomatous polyposis patients
(Bertagnolli et al., 2009). Long-term use of high doses of
COXIBs as chemopreventive strategy in sporadic CRC,
however, is not recommended because of the elevated
risk of potentially severe cardiovascular complications
(Cuzick et al., 2009).
The Membrane-Associated Guanylate Kinase (MA-
GUK) family member with Inverted domain structure-1
(MAGI1) consists of six PSD95/DiscLarge/ZO-1 (PDZ)
domains, a guanylate kinase domain and two WW
domains ﬂanked by two PDZ domains (Dobrosotskaya
et al., 1997). MAGI1 localizes to cell–cell contacts and
acts as a scaffold molecule to stabilize cadherin-mediated
adhesions and to recruit molecules at cell–cell contacts in
endothelial and epithelial cells (Laura et al., 2002).
Through its PDZ domains MAGI1 associates with a
variety of PDZ-binding molecules such as N-methyl-D-
aspartate receptors (Hirao et al., 1998), d-catenin (Ide
et al., 1999), brain speciﬁc angiogenesis inhibitor 1 (BAI-
1) (Mino et al., 2000), mNET1 (Dobrosotskaya, 2001),
phosphatase and tensin homologue (PTEN) (Kotelevets
et al., 2005) and b-catenin (Dobrosotskaya and James,
2000; Kawajiri et al., 2000). In epithelial cells MAGI1
localizes at adherens junctions in complex with b-catenin/
E-cadherin (Dobrosotskaya and James, 2000; Kawajiri
et al., 2000) as well as at tight junctions (Ide et al., 1999).
MAGI1 suppresses the invasiveness of Madin-Darby
Canine Kidney (MDCK) cells by recruiting PTEN to
cell–cell contacts and decreasing phosphatidylinositol-3-
OH kinase signaling (Kotelevets et al., 2005). TRIP6 has
been identiﬁed as a binding partner of MAGI1b in
epithelial cells that promotes MDCK invasiveness
through the activation of nuclear factor-kB and Akt
(Chastre et al., 2009). Taken together, MAGI1 is an
important molecule for the stabilization of cadherin-
mediated cell–cell interactions and the suppression of
invasiveness in non-transformed epithelial cells.
In an effort to identify COXIBs-regulated genes
affecting cancer progression, we have identiﬁed MAGI1
as COXIB-induced gene in CRC cells. MAGI1 pro-
motes E-cadherin and b-catenin recruitment to the
membrane, and suppresses TCF/LEF1 transcriptional
activity. It induces a cohesive epithelial cell phenotype,
decreases the migration and invasiveness of CRC cell
lines in vitro, and inhibits experimental CRC growth and
metastasis in vivo.
Results
COX-2 inhibition increases MAGI1 expression in CRC cells
Using a microarray-based screen in human umbilical
vein endothelial cells treated with the COXIB celecoxib,
we have recently identiﬁed genes regulated by celecoxib.
A total of 105 genes were downregulated with >2-fold
difference and 47 genes were upregulated with >2-fold
difference (false discovery rate (FDR)o0.05). MAGI1
mRNA was among the induced transcripts (FDR¼
0.0047) (J Zaric et al., unpublished data). As COX-2
promotes CRC (CRC) formation and progression
(Gupta, 2001), and COXIBs have protective effects, we
set up to test whether celecoxib modulated MAGI1
expression in CRC cells. Celecoxib treatment increased
MAGI1 mRNA and protein levels in the SW480,
HCT116, SW680, T84 and HT29 human CRC-derived
Figure 1 COXIBs induce MAGI1 expression in colorectal carci-
noma cells. (a) SW480 and HCT116 cells were cultured for 4 days in
the absence or presence of celecoxib at the indicated concentrations.
MAGI1 mRNA levels were measured by real-time RT–PCR (left
panels) and MAGI1 protein expression was analyzed by western
blotting (right panels). Celecoxib treatment induces MAGI1 mRNA
and protein expression. *Po0.001 compared with the untreated
control. (b) SW480 (left panel) and HCT116 (right panel) cells were
treated with the COXIB NS398 and the pan-COX-1/2 inhibitor
ibuprofen (IBP) for 4 days and subsequently analyzed for MAGI1
protein levels by western blotting. NS398 and IBP treatments induce
MAGI1 protein expression. (c) Western blotting showing MAGI1
and COX-2 levels in SW480 cells silenced for COX-2 (sh1-3) as
compared with WT and non-silenced (NS) control cells. COX-2
silencing enhances MAGI1 protein expression. (d) Western blotting
showing reduced MAGI1 protein in SW480 cells exposed to 16,16
dimethyl PGE2 (dmPGE2) for 24h. COX-2, cyclooxygenase-2;
COXIB, COX-2 inhibitor; MAGI1, MAGUKwith Inverted domain
structure-1; MAGUK, Membrane-Associated Guanylate Kinase;
PGE2, prostaglandin-E2; RT–PCR, reverse transcription–PCR;
WT, wild type.
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cell lines in vitro (Figure 1a and Supplementary Figure
S1a). MAGI1 was abundant in the DLD1 cell line (Stolﬁ
et al., 2008) expressing only trace amounts of COX-2
protein and mRNA (Supplementary Figures S1b and
S1c), and no increase was observed in response to
celecoxib (Supplementary Figure S1a). Treatment of
SW480 and HCT116 cells with NS-398, another COX-2-
speciﬁc inhibitor, and ibuprofen, a pan-COX-1/2
inhibitor, also increased the MAGI1 protein level
(Figure 1b). Silencing of COX-2 expression in SW480
cells using three different COX-2 short-hairpin RNAs
(shRNAs) resulted in increased MAGI1 expression
(Figure 1c). SW480 and HCT116 cells express mostly
the prostaglandin-E2 (PGE2) receptor EP4 (Supplemen-
tary Figure S1d), and treatment of SW480 cells with the
stabilized PGE2 analog, 16,16 dimethyl PGE2, resulted
in a decrease of MAGI1 protein and mRNA levels
(Figure 1d and Supplementary Figure S1e). SW480 and
HCT116 cells were used for subsequent experiments.
To obtain evidence that COX-2 also regulates
MAGI1 expression in vivo, we injected SW480 cells
subcutaneously into Swiss nu/nu mice and when tumors
were palpable we fed the mice either with a celecoxib-
supplemented diet or a conventional diet. Celecoxib
treatment signiﬁcantly reduced tumor growth (Supple-
mentary Figure S2a), consistent with ﬁndings in other
tumor models (Gupta et al., 2007), and increased
MAGI1 levels (Supplementary Figure S2b).
From these results, we conclude that the MAGI1
mRNA and protein are induced by celecoxib in CRC
cell lines in vitro and in derived tumors in vivo, and that
PGE2 suppresses MAGI1 expression.
MAGI1 promotes an epithelial morphology and inhibits
the migration, invasion and adhesion-independent growth
of CRC cells
In order to investigate the effects of MAGI1 in CRC
cells, we generated SW480 and HCT116 cells over-
expressing MAGI1 or with silenced MAGI1 (Supple-
mentary Figure S3). Parental SW480 cells consist of a
mixture of adherent and loosely attached, rounded cells,
often overgrowing as cell aggregates (Figure 2a, top
row). MAGI1-overexpressing SW480 cells acquired a
ﬂattened, epithelial-like morphology, whereas MAGI1-
silenced cells acquired a round shape and grew in
clusters. Staining for F-actin and paxillin showed
cortical actin, stress ﬁbers and paxillin-positive focal
adhesions in SW480 WT cells. MAGI1-overexpressing
cells have mostly stress ﬁbers and well-formed focal
adhesions, whereas MAGI1-silenced cells had no stress
ﬁbers, some cortical actin and no paxillin-positive focal
adhesions (Figure 2a, middle and lower rows). In
MAGI1-overexpressing SW480 cells, E-cadherin loca-
lized predominantly at cell–cell junctions, whereas in
MAGI1-silenced cells E-cadherin localization at cell–cell
contacts was largely lost (Figure 2b). MAGI1 over-
expression reduced SW480 cell migration and sup-
pressed Matrigel invasion, whereas MAGI1 silencing
facilitated migration and invasion (Figure 2c). Identical
results were obtained using HCT116 cells (Supplemen-
tary Figure S4a). MAGI1 silencing promoted and
MAGI1 overexpression reduced SW480 anchorage-
independent colony formation in an agarose assay
(Figure 2d). MAGI1 overexpression or silencing had
minor but signiﬁcant effects on cell growth in two-
dimensional conditions (Supplementary Figure S4b).
These results show that MAGI1 reverses the in vitro
cell-autonomous traits of malignancy in CRC cells,
including morphology, motility, invasion and ancho-
rage-dependent growth.
MAGI1 promotes integrin-mediated cell adhesion and
signaling
To address whether MAGI1 might modify cell adhesion
to extracellular matrix proteins, we performed short-
term in vitro adhesions assays. MAGI1 overexpression
enhanced and MAGI1 silencing decreased SW480
adhesion to collagen-I, ﬁbronectin and laminin
(Figure 3a). Enhanced adhesion was not associated with
increased cell-surface integrin expression and could be
prevented by using anti-integrin function-blocking anti-
bodies (Supplementary Figures S5a and S5b). MAGI1
overexpression in SW480 cells enhanced the phosphor-
ylation of focal adhesion kinase (FAK), extracellular
signal-regulated kinase-1/2 (ERK1/2) and Akt (Figures
3b and c), three kinases activated by out-side-in integrin
signaling (Cabodi et al., 2010). Increased FAK, ERK1/2
and Akt phosphorylation was transient and no longer
detectable 60min after adhesion.
These results show that MAGI1 enhances integrin-
mediated cell adhesion and out-side-in signaling.
MAGI1 inhibits Wnt/b-catenin signaling in CRC cells
Activation of the Wnt/b-catenin pathway is considered
as an initiating event in human colorectal cancerogenesis
(Clevers, 2006). As b-catenin was shown to bind
to MAGI1 in adherens junctions in epithelial cells
(Dobrosotskaya and James, 2000), we speculated that
MAGI1 expression levels might modulate the Wnt/b-
catenin pathway. To address this issue, we ﬁrst analyzed
the effect of MAGI1 on the activity of the b-catenin-
regulated TCF/LEF1 transcriptional complex using the
TCF/LEF1 luciferase reporter system TOPFlash/FOP-
Flash. MAGI1 overexpression in SW480 decreased
TCF/LEF1 transcriptional activity, whereas MAGI1
silencing increased the same (Figure 4a). Consistent with
these results, MAGI1 overexpression reduced axin-2
and c-Myc levels, two b-catenin/TCF/LEF1 target
genes, whereas MAGI1 silencing increased their expres-
sion (Figures 4b and c and Supplementary Figure S6). In
MAGI1-overexpressing SW480 cells b-catenin was
predominantly located at the cell membrane, whereas
in MAGI1-silenced cells it was diffuse in the cytoplasm
(Figure 4d), consistent with the modulation of the
Wnt/b-catenin pathway by MAGI1.
Taken together, these results show that MAGI1
inhibits Wnt/b-catenin signaling in CRC cells.
MAGI1 overexpression suppresses tumor cell growth and
spontaneous lung metastasis
Next, we tested whether changes in MAGI1 levels might
modulate SW480 and HCT116 tumor growth and
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Figure 2 MAGI1 modulates morphology, migration, invasion and anchorage-independent growth. (a) Phase-contrast microscopic
images (upper row), and immunostaining of F-actin (phalloidin, middle row) and paxillin (paxillin) of WT, MAGI1-overexpressing and
MAGI1-silenced SW480 cells. Nuclei were counterstained with 4,6-diamidino-2-phenylindole. MAGI1 overexpression induced a ﬂattened
epithelial morphology, actin stress ﬁber and paxillin-positive focal adhesion formation, whereas MAGI1 silencing caused cell rounding and
aggregation, and loss of actin stress ﬁbers and focal adhesions. (b) Confocal immunoﬂuorescence imaging showing that in SW480 cells E-
cadherin localized both at cell junctions and the cytoplasm. MAGI1 overexpression promoted localization at cell–cell junctions, whereas
MAGI1 silencing disrupted E-cadherin localization at cell–cell contacts. (c) Effect of MAGI1 overexpression silencing on the cell migration
(left panel) and invasion (right panel) of serum-starved SW480 cells. The results represent the average number of cells per ﬁeld±s.d.
counted on the lower side of the insert membrane. *Po0.001 compared with the WT (n¼ 3). (d) SW480 WT, SW480-overexpressing and
SW480-silenced cells grown in soft agar. MAGI1 silencing favors anchorage-independent growth of SW480 cells, whereas MAGI1
overexpression inhibits the same. The quantitative results are expressed on the right as mean value of triplicate determinations±s.d.
*Po0.05 compared with the WT (n¼ 3). MAGI1, MAGI1-overexpressing; MAGI1, MAGUK with Inverted domain structure-1;
MAGUK, Membrane-Associated Guanylate Kinase; shMAGI1, MAGI1-silenced; shNS, non-silenced control; WT, wild type.
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progression by injecting WT, MAGI1-silenced or
MAGI1-overexpressing SW480 and HCT116 tumor
cells subcutaneously into immunodeﬁcient mice.
MAGI1 overexpression strongly suppressed tumor
growth, whereas silencing of MAGI1 resulted in a
modest increase in tumor size as compared with that of
control tumors (Figures 5a and b). Histological analyses
of the primary tumors, lungs and livers showed no
evidence of local invasion or metastasis (data not shown).
To test whether MAGI1 overexpression was essential for
the tumor-suppressive effects of celecoxib, we injected
mice with SW480 cells non-silenced or silenced for
MAGI1 expression and treated one cohort of mice with
celecoxib. MAGI1-silenced cells were slightly but sig-
niﬁcantly (Po0.04) less sensitive to the effect of celecoxib
(Figure 5c). This suggests that celecoxib acts through
MAGI1-dependent and MAGI1-independent mechan-
isms. One possible MAGI1-independent mechanism is
inhibition of angiogenesis (Gupta and Dubois, 2001).
Indeed, microvascular density was decreased in celecoxib-
treated tumors, regardless of the MAGI1 status (Supple-
mentary Figure S7a).
As subcutaneous transplantation models are not well
suited for studying metastasis, we interrogated the role of
MAGI1 on metastasis formation using an orthotopic
implantation model (Cespedes et al., 2007). This model
produces metastases in almost all clinically relevant sites
occurring in human patients: regional and occasionally
distal lymph nodes, liver, lungs and peritoneum.
Luciferase-expressing WT, MAGI1-overexpressing and
MAGI1-silenced SW480 cells were implanted orthoto-
pically in the cecum of NOD/SCIDcg-null mice (NSG)
mice. Luminescence detection showed a 1-log increase
in the signal from in MAGI1-silenced SW480 tumors
as compared with that from SW480 WT tumors, and a 3-
log decrease in the signal from MAGI1-overexpressing
SW480 tumors as compared with that from WT tumors
(Figure 5d and Supplementary Figure S7b). SW480
tumors metastasized to the lung as detected by the
luminescence signal in the thorax region starting week 4
(Figure 6a). MAGI1 overexpression consistently sup-
pressed the luciferase signal fully in the lungs, whereas
MAGI1 silencing enhanced the same, however, with
great variability (Figure 6a). Histological analysis of
lungs, liver and mesenteric tissue conﬁrmed the presence
of metastases in the lungs and mesenterium of mice
bearing WT and MAGI1-silenced tumors, whereas
liver was metastasis-free (Figure 6b and data not shown).
MAGI1 overexpression suppresses experimental SW480
metastasis to the lung
As MAGI1-overexpressing SW480 tumors suppress
primary tumor growth, it is possible that the observed
reduced formation of spontaneous lung metastases is
because of the fact that primary tumors are small. To
address this possibility, we injected WT and MAGI1-
overexpressing SW480 into the tail vein of mice, and 4
weeks later we analyzed the lungs for the presence of
metastases. MAGI1 overexpression signiﬁcantly de-
creased both the number of nodules and their size,
thereby showing an affect of MAGI1 in metastasis
seeding and outgrowth (Figures 6c and d).
In conclusion, SW480 tumor transplantation experi-
ments showed that MAGI1 overexpression suppresses
primary tumor growth, metastasis seeding and metas-
tasis growth.
Figure 3 MAGI1 promotes integrin-mediated cell adhesion and
signaling. (a) Short-term adhesion assay of WT, MAGI1-over-
expressing and MAGI1-silenced SW480 cells on ﬁbronectin,
collagen-I and laminin. MAGI1 overexpression strongly enhanced
adhesion. The results represent the mean±s.d. of four replicate
experiments. *Po0.001 compared with the WT (n¼ 3). (b) Western
blot analysis of Y925-FAK phosphorylation and total FAK of
SW480 serum starved for 12 h and left to adhere to collagen-I for
30min. (c) Western blot analysis of phospho-T202/Y204-ERK1/2 and
total ERK1/2, and phospho-S473-Akt and total Akt, of SW480 cells
serum starved for 12 h and left to adhere to collagen-I for 30 or
60min. Actin immunoblotting shows equivalent protein loading
across different lanes. WT, wild type; MAGI1, MAGI1-over-
expressing; shMAGI1, MAGI1-silenced; shNS, non-silenced
control. ERK, extracellular signal-regulated kinase; FAK, focal
adhesion kinase; MAGI1, MAGUK with Inverted domain
structure-1; MAGUK, Membrane-Associated Guanylate Kinase.
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Increased colorectal mucosal levels of COX-2 and PGE2
are observed in colon adenoma and CRC, and are
implicated in colorectal carcinogenesis (Gupta, 2001).
Two distinct, complementary tumor-promoting effects of
COX-2 have been reported. First, COX-2 induces
modiﬁcations of the tumor stroma, promoting tumor
progression (Gupta and Dubois, 2001). For example,
COX-2 promotes tumor angiogenesis by stimulating the
expression of vascular endothelial growth factor in tumor
and stromal cells (Tsujii et al., 1998), enhancing vascular
endothelial growth factor mitogenic activity in endothelial
cells (Jones et al., 1999) and aVb3-dependent activation of
Rac-1 and Cdc42 (Dormond et al., 2001). Second, COX-2
directly stimulates tumor cell survival, proliferation,
migration and invasion in conjunction with oncogenic
pathways. For example, activation of HER2/HER3
heterodimers in CRC cells induces COX-2 expression
and PGE2 production (Vadlamudi et al., 1999), which
transactivates the epidermal growth factor receptor and
activates ERK, resulting in increased cell migration and
proliferation (Pai et al., 2002; Shao et al., 2003). COX-2
also cross-talks with the Wnt pathway (Wang et al., 2004).
PGE2 treatment of mice harboring a heterozygous APC
mutation (APC min), a murine model of familial
adenomatous polyposis, accelerates polyp formation
(Sonoshita et al., 2001). PGE2 was subsequently found
to induce the dephosphorylation of b-catenin resulting in
increased nuclear translocation and TCF/LEF1 activation
through activation of the phosphatidylinositol-3-OH
kinase/Akt pathway and inhibition of glycogen synthase
Figure 4 MAGI1 overexpression inhibits Wnt signaling. (a) Measurement of TCF/LEF1 transcriptional activity using the TOPFlash/
FOPFlash assay in SW80 cells. MAGI1 silencing enhanced TOPFlash activity, whereas MAGI1 overexpression decreased the same.
*Po0.001 compared with WT (n¼ 3). (b) Real-time RT–PCR analysis showing that MAGI1 silencing enhances axin-2 mRNA level
whereas MAGI1 overexpression decreases the same. The results represent the mean values±s.d. of fold difference relative to the axin-2
level in WT cells normalized to GAPDH levels. *Po0.001 compared with the WT. (c) Left panel: Western blot analysis showing that
MAGI1 overexpression represses c-Myc expression in SW480 cells, whereas MAGI1 silencing induces the same. Right panel: Western
blot analysis of SW680 and HCT116 cells showing that MAGI1 reduces c-Myc expression. Actin immunoblotting shows equivalent
protein loading. (d) Confocal immunoﬂuorescence images of SW480 cells showing that MAGI1 overexpression promotes b-catenin
localization at cell–cell junctions, whereas MAGI1 silencing disrupts the same. WT, wild type; MAGI1, MAGI1-overexpressing;
shMAGI1, MAGI1-silenced; shNS, non-silenced control. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MAGI1, MAGUK
with Inverted domain structure-1; MAGUK, Membrane-Associated Guanylate Kinase; RT–PCR, reverse transcription–PCR;
TCF/LEF1, T-cell factor/lymphoid enhancer-binding factor-1.
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kinase-3b (Castellone et al., 2005; Buchanan and DuBois,
2006). Consistent with such a mechanisms, COX-2
inhibition by celecoxib reduced polyp formation (Swamy
et al., 2006). Furthermore, COX-2 itself is a Wnt target
(Howe et al., 1999). Expression of Wnt-activating, mutant
b-catenin induces COX-2 expression, whereas inhibition
of the Wnt pathway by the APC protein suppresses
COX-2 expression in CRC cell lines (Araki et al., 2003;
Tuynman et al., 2008).
Here we report a previously unrecognized mechanism
by which COX-2 inhibition impinges on the Wnt/b-
catenin signaling pathway, namely through upregulation
of MAGI1, a multi-domain scaffolding molecule present
at adherens junctions in complex with E-cadherin/b-
catenin. CRC cells treated in vitro with the COXIBs
celecoxib and NS398, or the pan-COX-1/2 inhibitor
ibuprofen, expressed more of the MAGI1 mRNA and
protein. The induction of MAGI1 upon COX-2 silen-
cing shows that this activity was not because of the
off-target effects of COXIBs (Abassi et al., 2009). MAGI1
overexpression induced an epithelial-like morphology;
stabilized E-cadherin and b-catenin localization at cell–
cell junctions; increased paxillin-positive focal adhe-
sions, actin stress ﬁbers and cell adhesion to matrix
proteins; and suppressed TCF/LEF1 transcriptional
activity, anchorage-independent growth, migration and
invasion in vitro. MAGI1 silencing decreased E-cadherin
localization at cell–cell junctions, disrupted stress ﬁbers
and focal adhesions, and enhanced anchorage-indepen-
dent growth, migration, invasion and TCF/LEF activity
in vitro. MAGI1 overexpression in tumor cells in vivo
suppressed primary colorectal tumor growth and lung
metastasis formation in an intestinal orthotopic trans-
plantation CRC model and an experimental metastasis
model. These observations extend the published data on
the activities of MAGI1 in non-transformed cells and
uncover a previously unrecognized tumor-suppressive
role of MAGI1 in CRC. MAGI1, however, is not the
Figure 5 MAGI1 overexpression suppresses subcutaneous and orthotopic SW480 tumor growth. (a, b) WT, MAGI1-overexpressing
and MAGI1-silenced SW480 (a) and HCT116 cells (b) (1 106) were injected subcutaneously into immunocompromised mice. MAGI1
overexpression suppressed tumor growth whereas MAGI1 silencing tended to increase the same. The results represent mean tumor
volume±s.d. (seven mice per group). *Po0.05 compared with the WT. (c) MAGI1-silenced SW480 and non-silenced SW480 cells were
injected into NSG mice and the mice were maintained on normal diet or a celecoxib-supplemented diet. Celecoxib inhibited both
MAGI1-silenced and non-silenced tumors, but MAGI1-silenced tumors were less sensitive. *Po0.04 compared with shNSþ celecoxib.
(d) Luciferase-expressing SW480 cells were injected orthotopically (1 106) into the cecum of NSG mice and tumor growth was
monitored by detecting in vivo luciferase activity. The results represent mean photon values within the tumor region of interest.
*Po0.05, **Po0.001 compared with the WT (n¼ 2, 4 mice per group). MAGI1, MAGI1-overexpressing, MAGI1; MAGUK with
Inverted domain structure-1; MAGUK, Membrane-Associated Guanylate Kinase; NSG, NOD/SCIDcg-null mice; shMAGI1,
MAGI1-silenced; WT, wild type.
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only mediator of the antitumor activity of celecoxib.
Additional mechanisms are involved, as MAGI1 silen-
cing only partially blocked celecoxib from inhibiting
tumor growth. Inhibition of tumor-associated angio-
genesis is likely to contribute to this effect. In view of
the observed phenotypic and functional changes, we
considered the possibility that MAGI1 might modulate
epithelial-to-mesenchymal transition. We monitored the
expression levels of E-cadherin, N-cadherin, vimentin,
Zeb1 and high mobility group AT-hook2 (HMGA2) by
immunostaining and reverse transcription (RT)–PCR in
MAGI-overexpressing and -silenced SW480 cells but did
not observe any differences (data not shown). These
results suggest that MAGI1 modulates morphological
and functional (that is, invasion and migration) features
independently of epithelial-to-mesenchymal transition.
E-cadherin/b-catenin complexes are forming a signalo-
some that recruits multiple scaffolding molecules such as
Figure 6 MAGI1 overexpression suppresses metastases formation. (a) Spontaneous lung metastasis formation was monitored in vivo
by luciferase activity over the thorax region in mice bearing orthotopic SW480 tumors. The results represent the mean photon values
within the tumor region of interest. MAGI1 overexpression suppresses metastases formation. *Po0.05 compared with the WT (n¼ 3–4).
(b) Representative histological images (hematoxylin–eosin staining) conﬁrming the presence of metastases in lung and mesenteric
tissue. (c) Experimental lung metastasis assay. WT and MAGI1-overexpressing cells were injected into the tail vein and mice were
killed 4 weeks later. Lung metastases were quantiﬁed by counting the number of nodules per lung, and measuring the surface (as
surrogate of size) or individual nodules. MAGI1 overexpression suppresses both the number and the size of the metastatic nodules.
*Po0.01, **Po0.001 compared with the WT (n¼ 7). (d) Representative examples of lung metastases of WT (left) and MAGI1-
overexpressing (right) SW480 cells. MAGI1, MAGI1-overexpressing; MAGI1, MAGUK with Inverted domain structure-1; MAGUK,
Membrane-Associated Guanylate Kinase; shMAGI1, MAGI1-silenced; WT, wild type.
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MAGI1, PTEN (Kotelevets et al., 2005), Rap1 (Mino
et al., 2000) and TRIP6 (Chastre et al., 2009). The
stabilization of E-cadherin/b-catenin at the cell–cell
borders by MAGI1 overexpression and its loss from
cell–cell borders following MAGI1 silencing is consistent
with the model that MAGI1 suppresses Wnt/b-catenin
signaling by decreasing the pool of free b-catenin. This
model is also supported by the published evidence that the
COX-2 main product, PGE2, leads to the inactivation of
glycogen synthase kinase-3b, release of b-catenin from the
axin/APC complex and its translocation to the nucleus,
resulting in the activation of TFC/LEF1-dependent
transcription (Castellone et al., 2005; Shao et al., 2005).
As tumor cell exposure to PGE2 results in MAGI1
reduction, it is conceivable that inﬂammatory and cancer
conditions associated PGE2 production, as it occurs in
cancer, may cause a reduction of MAGI1 expression
resulting in facilitated Wnt/b-catenin signaling. It will be
important to unravel the signaling pathways linking
PGE2/E-prostane receptors to suppressed MAGI1 ex-
pression, and identify molecules representing potential
therapeutic targets, to maintain high MAGI1 levels under
conditions of elevated PGE2 production as an alternative
to COXIBs-based treatments. This could create new
opportunities to replace COXIB in pharmacological
approaches to prevent CRC in high-risk patients or to
treat manifest CRC, thereby potentially avoiding COXIB
cardiovascular side effects (Cha and DuBois, 2007). As
COX-2 activity suppresses E-cadherin expression in
intestinal epithelial cells (Tsujii and DuBois, 1995) and
COX-2 inhibition upregulates the same (Noda et al.,
2002), it will be important to assess whether there may be
a common circuitry that coordinates the disassembling E-
cadherin junctional complexes and the promotion of
b-catenin/TCF/LEF1 transcriptional activity in response
to COX-2 activation. A further question to address is,
whether MAGI1 could itself be downregulated by Wnt
signaling in CRC cells, thereby creating a self-sustaining
loop much alike COX-2, which is both a Wnt-activating
protein and a Wnt target gene (Araki et al., 2003;
Buchanan and DuBois, 2006). Interestingly, MAGI3 was
shown to bind to the Wnt receptors Frizzled-4 and
Frizzled-7 (Yao et al., 2004), and to Ltap, a protein
homologous to Stbm, which genetically interacts with
frizzled to regulate Wnt signaling in Drosophila (Taylor
et al., 1998; Wolff and Rubin, 1998). In epithelial cells,
MAGI3 and Frizzled-4 form a complex that localizes at
cell contact sites (Yao et al., 2004). Taken together, these
observations suggest that MAGI1 may be a physiological
regulator of Wnt signaling.
In conclusion, we have identiﬁed MAGI1 as a
COXIB-induced inhibitor of Wnt/b-catenin signaling




Bovine serum albumin, paraformaldehyde, poly L-lysine
(PLL), ﬁbronectin, laminin, gelatin and collagen-I were
purchased from Sigma Chemie (Buchs, Switzerland). The
antibodies used are as follows: anti-MAGI1 polyclonal anti-
body (M5691) and anti-actin monoclonal antibody (mAb),
phalloidin–ﬂuorescein isothiocyanate (from Sigma Chemie);
anti-paxillin (clone 349) (from Transduction Laboratories,
Lexington, KY, USA); anti-c-Myc mAb (sc-40) (from Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA); anti-COX-2
mAb (from Cayman Chemical; Chemie Brunschwig, Basel,
Switzerland); anti-b-catenin mAb (from Transduction Labora-
tories; BD Biosciences, Basel, Switzerland); anti-phospho-Y407-
FAK antibody (from Invitrogen, Basel, Switzerland); anti-
pY925-FAK, anti-human FAK antibody, anti-phospho-S473-
Akt, anti-Akt, anti-ERK1/2 and anti-phospho-T202/Y204-
ERK1/2 (from Cell Signaling Technology, Danvers, MA,
USA); anti-integrin function-blocking mAbs—mAbs Lia1/2
(anti-b1), and mAb GI9 (anti-a2) and GoH3 (anti-a6) (from
Beckman Coulter, Nyon, Switzerland); Sam-1 (anti-a5) and
LM609 (anti-aVb3) (from Millipore, Zug, Switzerland). The
biotinylated rat anti-CD31 mAb was from Pharmingen (San
Diego, CA, USA). Matrigel was purchased from BD
Biosciences, and NS-398 (Futaki et al., 1997) and ibuprofen
(Meade et al., 1993) were from Biomol (Enzo Life Sciences,
Lausanne, Switzerland). Celecoxib was provided by Pﬁzer AG
(Du¨bendorf, Switzerland). 16,16 dimethyl PGE2 was pur-
chased from Cayman (Ann Arbor, MI, USA). D-luciferin was
obtained from Caliper Life Sciences (Oftringen, Switzerland).
Cell lines and cell culture
The human colorectal carcinoma cell lines SW480, SW620,
HCT116, DLD1, HT29 and T84 were from American
Type Culture Collection (LGC Standards, Molsheim, France).
For all experiments, cells were grown in high-glucose
Dulbecco’s modiﬁed Eagle’s medium (HCT116, HT29 and
T84) or RPMI (SW480, SW620 and DLD1) supplemented
with 10% fetal calf serum and 1% penicillin/streptomycin, and
maintained in a humidiﬁed incubator at 37 1C under 5% CO2.
All cell culture reagents were purchased from Invitrogen. Cells
were treated with 50mM Celebrex, 100mM NS-398 and 50mM
ibuprofen for 4 days (medium with the appropriate drug was
changed daily).
In vitro migration and invasion assay
Assays were performed as described previously by Monnier
et al. (2008).
Cell adhesion and proliferation assays
Assays were performed as described previously by Zaric and
Ruegg (2005) and Bieler et al. (2007).
Soft agar assay
For soft agar assay, 5 103 cells were seeded in triplicate in
1ml of 0.3% (w/v) agar (Difco; BD Biosciences) in complete
Dulbecco’s modiﬁed Eagle’s medium (for HCT116) or RPMI
(for SW480) medium in six-well plates on 1ml of a 0.6%
bottom agar layer. The cells were fed twice a week and the
number of colonies per well was scored 4 weeks later: colonies
were counted in four random ﬁelds per well under a
microscope (n¼ 3). The results are presented as colonies per
ﬁeld and represent the mean values±s.d.
Luciferase assay
For dual luciferase reporter assays, SW480 and HCT116 cells
were transfected with the ﬁreﬂy luciferase reporter constructs
(TOPFlash or FOPFlash; Millipore-Upstate, Upstate, MA,
USA) and the control Renilla luciferase reporter pRL-TK
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(Promega, Du¨bendorf, Switzerland) using Lipofectamine
(Invitrogen). Cells were lysed 48 h after transfection using the
cell lysis buffer available in the dual-luciferase reporter assay
kit (Promega). Luciferase activity was then measured accord-
ing to the manufacturer’s instructions.
Immunoﬂuorescence microscopy
SW480 cells were cultured when they reached sub-conﬂuence
or at conﬂuence on glass coverslips pre-coated with collagen-I
(10mg/ml) placed in 12-well plates in complete RPMI medium
for 24–48 h. The cells were then ﬁxed in 4% paraformaldehyde
for 10min at room temperature, permeabilized with 0.1%
Triton X-100, blocked with 1% bovine serum albumin
and incubated for 1 h with the relevant primary antibodies
(5 mg/ml). After washing, the cells were incubated with a Cy5
or ﬂuorescein isothiocyanate-conjugated secondary antibody.
4,6-Diamidino-2-phenylindole was used to counterstain nuclei.
The stained cells were mounted in Prolong Antifade medium
(Molecular Probes (Basel, Switzerland), Invitrogen) and
viewed using a Zeiss LSM 510 Meta confocal microscope
(Carl Zeiss AG, Zu¨rich, Switzerland) and DeltaVision Elite
(Applied Precision, Issaquah, WA, USA).
Flow cytometric analysis
Stainings, data acquisition and analysis were performed as
described previously by Zaric and Ruegg (2005).
Western blot analysis
Cell lysis, sodium dodecyl sulfate–PAGE and blotting were
performed as described previously by (Monnier et al. (2008).
RT–PCR and real-time RT–PCR
Total RNA was prepared from cells using RNAsol B (Tel-Test,
Inc, Friendswood, TX, USA) and following the manufac-
turer’s instructions. A 5-mg weight of total RNA was reverse-
transcribed using random primers (Superscript II; Invitrogen).
RT–PCR was performed by cDNA, which was subjected to
PCR ampliﬁcations using primer pairs speciﬁc for EP1, EP2,
EP3 and EP4: EP1 (NM_000955.2): fw 5
0-ACCGACCTGG
CGGGCCACCTGA-30, rev 50-CGCTGAGCGTGTTGCAC
ACCAG-30; EP2 (NM_000956.3) fw 50-TCCAATGACTCC
CAGTCTGAGG-30, rev 50-TGCATAGATGACAGGCAGC
ACG-30; EP3 (NM_198717.1) fw 50-GATCACCATGCTGCT
CACTG-30, rev 50-AGTTATGCGAAGAGCTAGTCC-30;
EP4 (NM_000958.2) fw 5
0-GGGCTGGCTGTCACCGACC
TG-30, rev 50-GGTGCGGCGCATGAACTGGCG-30 (Micro-
synth, Balgach, Switzerland). The ampliﬁcation conditions
were as follows: 40 cycles of 30 s at 94 1C, 1min at 62 1C and
1min at 72 1C.
Real-time PCR was performed using the KAPA SYBR
FAST kit (KAPA Biosystems, Boston, MA, USA) and the
StepOnePlus machine (Applied Biosystems, Rotkreuz,
Switzerland). The primers used were as follows: MAGI1
(NM_001033057) fw 50-CGTAAAGTGGTTTTTGCGGTGC-30,
rev 50-TCTCCACGTCGTAGGGCTGC-30; axin-2 (Koch
et al., 2004) fw 50-GTGCAAACTTTCGCCAACCG-30, rev
50-GCTGGTGCAAAGACATAGCC-30; glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) fw 50-GGACCTGACC
TGCCGTCTAG-30, rev 50-CCACCACCCTGTTGCTGTAG-
30; COX-2 (PTGS2)(NM_000963.2) fw 50-GGCGCTCAGC
CATACAG-30, rev 50-CCGGGTACAATCGCACTTAT-30,
and were purchased from Microsynth. The sample series were
run three independent times. The average and standard
deviation were calculated for each sample.
Lentiviral constructs
The human MAGI1 cDNA was provided by Dr Y Hata
(Department of Medical Biochemistry, Graduate School of
Medicine, Tokyo Medical and Dental University, Tokyo, Japan)
and sub-cloned into the pRRLSIN.cPPT.PGK/GFP.WPRE
lentiviral vector under the control of the phospho glycerate
kinase (PGK) promoter (¼ pSD44 plasmid). For gene silencing
experiments, the pCMV-GIN-ZEO lentiviral shRNAmir-expres-
sing system was purchased from Open Biosystems (Huntsville,
AL, USA). For the shRNAmir sequences directed against the
human MAGI1, three different clones were obtained (clone
IDs: V2LHS-36239 (¼MAGI1shRNAmir#1)/V2LHS-36236
(¼MAGI1shRNAmir#2)/V2LHS-36238 (¼MAGI1shRNA
mir#3)) that consisted of the shRNAmir sequences cloned into
the pSHAG-MAGIC2 (pSM2c) retroviral vector. The three
shRNAmir sequences, or a non-silencing control shRNAmir
sequence that contains no homology to known mammalian
genes, were sub-cloned into the pCMV-GIN-ZEO lentiviral
system. For silencing of human COX-2 (PTGS2), three clones
were used, with the following clone IDs: V2LHS-6305
(¼COX-2shRNAmir#1)/V2LHS-131533 (¼COX-2shRNA-
mir#2)/V2LHS-131532 (¼COX-2shRNAmir#3). The lucifer-
ase-expressing lentiviral vector for in vivo cell tracking, pLV-
CAG-Luci-IRES-PuroR, was a gift from Dr M Aguet (ISREC-
EPFL, Lausanne, Switzerland). Lentiviruses were produced in
293T cells by following the calcium phosphate transfection
method by co-transfecting the pCMV-GIN-ZEO constructs or
the pSD44-MAGI1 cDNA with the pMD2G plasmid (VSV-G
viral envelope construct) and the pMDLgpRRE plasmid. Cell
cultures were transduced by overnight incubation at 37 1C in
virus-containing media in the presence of 8mg/ml polybrene.
Selection was started on bulk cultures 48 h after transduction
using 2mg/ml puromycin (Sigma Chemie) for the pSD44-
MAGI1-cDNA construct or 800mg/ml G418 (Calbiochem,
San Diego, CA, USA) for the pCMV-GIN-ZEO constructs.
In vivo studies
Subcutaneous implantation model. SW480 cells (1 106) and
derived lines were injected subcutaneously into Swiss nu/nu
female mice (6–8 weeks) and HCT116 cells (1 106) were
injected subcutaneously into NSG mice. Tumor volume was
calculated using the following formula: length (width)2
0.52. For celecoxib treatment, mice were randomized at day 7
and assigned to a treated (that is, celecoxib mixed with a
powdered rodent chow diet (2018 Global Rodent diet; Harlan
Teklad Europe, Lyon, France) at 1000 p.p.m. (¼ 1g/kg chow)
and provided continuously during the course of the experi-
ment) or an untreated group (chow without celecoxib). This
protocol allowed attaining celecoxib serum concentrations that
are clinically relevant as shown previously by Jacoby et al.
(2000) and Gupta et al. (2007).
Orthotopic transplantation model. SW480 cells were tagged
with ﬁreﬂy luciferase using lentiviral transduction. The cecum
was exteriorized by laparotomy and 1 106 cells in 20ml of
Matrigel/RPMI solution were injected into a single spot in the
cecal wall using a Hamilton syringe under binocular guidance.
The injected cecum was returned to the abdominal cavity and
the wound was sutured. The development of primary tumors
and metastatic spread was monitored weekly using the IVIS
Xenogen Imaging System (Caliper Life Sciences) after intra-
peritoneal injection of 150mg/kg D-luciferin. The results are
expressed as photon emission within the ‘region of interest’.
Experimental metastasis model. SW480 cells (1 106) were
injected into the tail vein of 10-week-old NSG females. The
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mice were killed 4 weeks later and serial sections of parafﬁn-
embedded lungs were hematoxylin–eosin-stained. The number
of metastases was quantiﬁed by counting nodules manually
and quantifying the surface (using the ImageJ software; NIH)
of six sections per lung per animal. The results are presented as
the average of the number of metastasis per lung±s.d. and
surface of individual metastasis±s.d. (in arbitrary values).
Histopathological and immunohistochemical analyses
Standard hematoxylin–eosin staining procedures were per-
formed on parafﬁn-embedded tissues. For immunohisto-
chemical detection of micro-vessels, tissue was stained with
biotinylated rat anti-mouse CD31 as described earlier by
Monnier et al. (2008).
Statistical analysis
Statistical signiﬁcance was determined by Student’s t-test.
P-value o0.05 was considered signiﬁcant.
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